Match Document Document Title
5242810 Bifunctional inhibitors of thrombin and platelet activation  
The present invention relates to novel, bifunctional inhibitors of both platelet activation and thrombin. These bifunctional inhibitors are characterized by two domains -- a glycoprotein IIb/IIIa...
5239059 Ion-channel forming peptides  
A biologically active peptide which includes the following structure: R1 --R1 --R1 --R3 --R5 --R1 --R1 --R1 --R1 --R1 --R2 --R2 --R1 --R1 R3 -- R1 --R4 --R1 --R3 --R4 --R1 --R1. R1 is a...
5238821 Endo F-free PNGase  
An enzyme sample having Peptide-N4 -(N-acetyl-β-N-glucosaminyl) asparagine Aminidase F (PNGase F) activity completely free from Endo-β-N-acetylglucosaminidase F (Endo F) activity.
5236903 Polypeptide comprising repeated cell-adhesive core sequences  
A polypeptide comprising repeated amino acid sequences of a cell-adhesive protein represented by the formula: (Arg-Gly-Asp)n or (Tyr-Ile-Gly-Ser-Arg)nwherein n is a number ranging from 2 to 20; or...
5236898 Cyclic anticoagulant peptides  
This invention relates to cyclic peptide derivatives which are useful anticoagulant agents.
5234907 Synthetic vasoactive intestinal peptide analogs  
Vasoactive intestinal compound analogs containing substitutions of appropriately selected amino acids at specific positions of the VIP molecule.
5229490 Multiple antigen peptide system  
Multiple antigen peptide systems are described in which a large number of antigens are bound to the functional groups of a dendritic core molecule providing a high concentration of antigen in a...
5225193 Bordetella toxin peptides and vaccines  
The following new polypeptides are described: (a) H-X1 -Asp-Asp-Pro-Pro-Ala-Thr-Val-Tyr-Arg-Tyr-Asp-Ser-Arg-Pro-Pro -Glu-Asp-X.sup .2 -Y, (b) H-X1...
5223423 Characterization of replication competent human immunodeficiency type 2 proviral clone HIV-2SBL/ISY  
A complete genomic clone of HIV-2 designated HIV-2SBL/ISY was cloned from DNA of the neoplastic human cell line HUT78 infected with the HIV-2SBL6669 viral isolate. The clone was sequenced and the...
5223605 Interleukin-4 binding protein-γ  
Isolated and purified Interleukin-4 Binding Protein-γ (IL-4bpγ) and methods for obtaining isolated and purified IL-4bpγ.
5217861 Antigen of a human retrovirus, namely p18 protein of human immunodeficiency virus (HIV), compositions containing the antigen, a diagnostic method for detecting acquired immune deficiency syndrome (AIDS) and pre-AIDS and a kit therefor  
Protein compositions containing proteins of the lymphadenopathy virus, which compositions are used for diagnosis of antibodies of such protein in biological fluids, especially blood serum, for the...
5217953 Vasoactive intestinal peptide antagonist  
The present invention relates to a peptide encoding an antagonist of VIP. The invention also relates to a method of using said peptide to antagonize VIP function. The invention further relates to...
5218091 Glycolytic promoters for regulated protein expression: protease inhibitor  
Promoters associated with expression of specific enzymes in the glycolytic pathway are used for expression of alien DNA, particularly yeast promoters known to provide high enzyme levels of enzymes...
5218092 Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains  
A polypeptide or glycosylated polypeptide with at least one new carbohydrate chain produced by means of recombinant DNA technique, which has protease resistance and thermal stability and is...
5217705 Method of diagnosing blood clots using fibrin-binding proteins  
A fibrin-binding protein such as t-PA is labeled with a detectable substance, such as a radionuclide, and administered to a patient for diagnosis of blood clots and for monitoring the dissolution...
5214031 Growth-inhibitory factor obtained from human brain  
Disclosed are a growth-inhibitory factor which is a pure protein extracted from human brain and having inhibitory action against neurotrophic activity and a cDNA coding for a protein existing in...
5212154 Preparation for treating complications in diabetes  
Preparation for preventing or combating complications in diabetes, characterized in that it comprises: (a) insulin or a salt or complex thereof, and (b) a peptide of the general formula I:...
5210181 T-lymphotropic retrovirus peptide  
The instant invention relates to monoclonal antibodies, the cell lines producing those antibodies, the peptides that comprise the epitopes of those antibodies and assays using those antibodies and...
5208218 T cell growth factor glycoproteins  
The present invention relates generally to a T cell growth factor. More particularly, the present invention relates to a T cell growth factor which comprises a glycoprotein which supports...
5206343 Oligopetides with cyclic proline-analogous amino acids  
The invention relates to compounds of the formula I ##STR1## in which A denotes an optionally substituted radical from the series comprising alkyl, acyl, cycloalkyl, aryl and heteroaryl; Cyc...
5206344 Interleukin-2 muteins and polymer conjugation thereof  
Muteins of IL-2 in which one of the amino acids of the mature native sequence of IL-2 is replaced by a cysteine residue are prepared and conjugated through the replaced cysteine residue to a...
5204258 Gene expressing VPT protein and vectors expressing this protein  
Viral protein T from Human Immunodeficiency Virus Type 1 (HIV-1) is disclosed. The protein has a molecular weight of approximately 17 kD and is produced by the vpt gene of HIV-1. This protein is...
5204259 Methods and systems for producing HIV antigens  
The present invention relates to a DNA segment encoding a recombinant HIV p24 protein or HIV p24-gp41 fusion protein and a recombinant DNA (rDNA) molecule capable of expressing either protein....
5202419 Anticoagulative protein PP4-X  
The protein PP4-X, whose amino acid sequence and the DNA sequence coding for this have been determined, has anticoagulative properties and can be prepared by genetic manipulation. PP4-X is used...
5200176 Method for protection of ischemic tissues using tumor nerosis factor  
Methods suitable for the protection, inhibition and prevention the deleterious effects of reactive oxygen species are provided, wherein an effective amount of a tumor necrosis factor is...
5198536 Peptides comprising an immunogenic site of poliovirus and DNAs containing nucleotide sequences coding for these peptides  
The invention relates to a DNA fragment containing at the most 315 pairs of nucleotides coding for a peptide which can be recognized by antibodies acting both against the "C" and "D" particles of...
5198349 Method for producing factor VIII:C and analogs  
An improved method for producing Factor VIII:c is disclosed. The method involves culturing mammalian cells which contain DNA encoding Factor VIII:c and which are capable of expressing Factor...
5198421 Phosphorylated cyclic lipopeptide  
There is disclosed a monophosphorylated cyclic lipopeptide compound obtained by biophosphorylating a cyclic lipopeptide related to echinocandins and having a peptide skeleton bearing several...
5198533 LHRH antagonists  
The present invention deals with LHRH antagonists which possess improved water solubility and while having the high antagonist potency of the basic peptides, are free of the edematogenic effects....
5196524 Fusion reporter gene for bacterial luciferase  
Novel fusion reporter genes, fusion reporter proteins, and an improved reporter system for measuring the relative activity of a promoter sequence. A luxAB fusion gene of the present invention is...
5196512 Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines  
The synthetic peptide TT3, the amino acid sequence of which corresponds to the region 947-967 of the tetanus toxin is recognized by different human Th cell clones in association with a wide range...
5192742 Compounds and compositions for the treatment of bacterial infections in animals  
New glycopeptide antibiotics MM 49728, MM 55266, MM 55267/1, MM 55267/2 and MM 55268 are produced by fermentation of Amycolatopsis sp. NCIB 40089.
5190922 Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands  
Oligopeptide compounds or oligopeptide analogue compounds of the formula A-B-D-E-G-J-L are ligands for the anaphylatoxin receptor and are useful in the treatment of inflammatory disease states....
5190873 Hybrid tryptophan aporepressor containing ligand binding sites  
Hybrid proteins containing repressor proteins and substituted receptor binding sites, amino acid and DNA sequences encoding the hybrid proteins are provided. Methods for preparing the hybrid...
5189019 Antistasin derived anticoagulant protein  
A protein having a molecular weight of about 6,000 daltons which is biologically active in the inhibition of Factor Xa during the blood coagulation cascade, a method for producing the protein,...
5187156 Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same  
The present invention relates to DTrp-Phe containing tripeptides and pharmaceuticals, which possess tachykinin antagonism activity as well as processes of making such peptides.
5187153 Methods of treatment using Alzheimer's amyloid polypeptide derivatives  
Pharmaceutical compositions containing a 57 amino acid protease inhibitor and uses for those compositions are taught. The protease inhibitor is referred to as A4i which is associated with...
5185147 Short polypeptide sequences useful in the production and detection of antibodies against human immunodeficiency virus  
Polypeptides in the size range 6-11 amino acids from discrete regions of the human immunodeficiency virus p17 protein are immunogenic and form the basis for diagnosis and therapy of HIV-related...
5182204 Non-human carbonyl hydrolase mutants, vectors encoding same and hosts transformed with said vectors  
Novel carbonyl hydrolase mutants derived from the DNA sequences of naturally-occurring or recombinant non-human carbonyl hydrolases. The mutant carbonyl hydrolases, in general, are obtained by in...
5180811 Proteins having a TNF action comprising TNF-fibromectin fusion protein  
Derivatives of a tumor necrosis factor (TNF), which originate from a modification at the amino terminus of the TNF molecule are suitable for controlling diseases.
5177188 Methods and compositions for diagnosing chronic immune thrombocytopenic purpura  
A polypeptide consisting essentially of an amino acid residue sequence selected from the group consisting of: Tyr-His-Asp-Arg-Lys-Glu-Phe-Ala-Lys-Phe-Glu-Glu-Glu-Arg-Ala- ...
5175097 Expression and diagnostic use of GAG-1 encoded peptides which are immunologically reactive with antibodies to HIV  
Immunologically reactive gag proteins of LAV/HTLV-III are expressed in bacterial cells. The gag proteins are encoded by a recombinant plasmid containing procaryotic transcriptional and...
5175098 Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to HIV  
Immunologically reactive gag proteins of LAV are expresesed in bacterial cells. The gag proteins are encoded by a recombinant plasmid containing procaryotic transcriptional and translational...
5175251 Antimetastatic peptides with laminin activity  
Human laminin B1 peptides have been produced. The invention provides novel peptides which contain substantial amino acid sequence similarity to amino acids 897 to 936 in the human sequence. These...
5171835 LHRH antagonists  
Disclosed herein are analogues of the luteinizing hormone-releasing hormone (LH-RH), which are potent antagonists of LH-RH. These peptides inhibit the release of gonadotropins from the pituitary...
5169833 Substituted cyclic pentapeptides  
The present invention provides substituted cyclic pentapeptide compounds of general Formula I: ##STR1## and the pharmaceutically-acceptable slats, esters and amides thereof, which are useful for...
5169763 Viral vector coding glycoprotein of HIV-1  
A viral vector comprising at least a portion of the genome of the HIV virus, a gene coding gp160 glycoprotein of the envelope of the HIV virus, as well as the elements providing for the expression...
5166322 Cysteine added variants of interleukin-3 and chemical modifications thereof  
Cysteine added variants ("CAVs") of interleukin-3 are provided having one or more cysteine residues substituted for selected naturally occurring amino acid residues, or inserted into the...
5166316 Physiologically active peptides and a method of producing peptides  
Novel peptides which can be synthesized chemically or by recombinant means, including a peptide having the amino acid sequence, H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-...
5164370 Peptide analogues of insulin-like growth factor 1 (IGF-1) or factor 2 (IGF-2)  
Peptide analogues of insulin-like growth factor 1 and growth factor 2 are disclosed. When the analogue is an analogue of growth factor 1 the glutamic acid residue is absent from position 3 of the...